Epista Life Science A/S: Financial statements 2012
CVR: 32141064
Source: annual report 2012, Danish Business Authority
01/01/2012 – 31/12/2012
Epista Life Science A/S (CVR 32141064) has filed annual accounts for 2012. In 2012, the company reported a gross profit of DKK 7,785,482 and a net result of DKK 470,832. Equity in the 2012 report amounted to DKK 678,037. The solvency ratio was 25.1%.
- Gross Profit
- DKK 7,785,482
- Profit/Loss
- DKK 470,832
- Equity
- DKK 678,037
- Total Assets
- DKK 2,698,437
Official annual report
Keep an eye on Epista Life Science A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2012
As of October 31, 2012, Martin Woergaard has stepped down as director of Epista Life Science A/S.
As of July 1, 2012, Beierholm Godkendt Revisionspartnerselskab has been appointed auditor of Epista Life Science A/S.
As of July 1, 2012, Revision Syd I/S has stepped down as auditor of Epista Life Science A/S.
About Epista Life Science A/S
Epista Life Science A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2009. The company is registered under the industry Computerkonsulentbistand og forvaltning af computerfaciliteter. The company was previously named EPISTA IT A/S and EPISTA IT ApS. The management consists of Per Erik Mikael Johansson. The board consists of Simon Carl Vilhelm Larsson (chair), Katarína Larsen and Klavs Esbjerg. The company is owned by Enhance BidCo ApS. The company has 86 employees (2026). In 2025, the company reported a gross profit of DKK 104,009,512 and a net result of DKK -40,340,814 compared with DKK -12,458,230 the year before. Equity in the 2025 report amounted to DKK 42,811,282.